Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Bear Stearns Upgrades CV Therapeutics


Bear Stearns upgrades CV Therapeutics (CVTX) to peer perform.

Analyst Akhtar Samad says CV Therapeutics said Phase III ERICA study of Ranexa met its primary endpoint of statistically significant reduction in angina frequency in patients taking maximally prescribed dose of amlodipine.

He notes patients entering ERICA trial had aproximately 5.5 angina events per week, with placebo arm demonstrating 3.2 events per week. He says patients administered 1000 mg Ranexa BID exhibited a 0.4 angina event per week reduction from placebo, or an about 12% to 13% benefit.

Management notes improvement correlated to aproximately 30% to 33% improvement in quality of life measure.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus